HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schumock, G. T. Articles by Pickard, A. S. Search for Related Content PubMed PubMed Citation Articles by Schumock, G. T. Articles by Pickard, A. S.

GLEN T. SCHUMOCK, PHARM.D., M.B.A., FCCP, is Director, Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago (UIC), and Associate Professor, Department of Pharmacy Practice, College of Pharmacy, UIC. A. SIMON PICKARD, B.S.PHARM., PH.D., is Assistant Director, Center for Pharmacoeconomic Research, College of Pharmacy, UIC, and Associate Professor, Department of Pharmacy Practice, College of Pharmacy, UIC.

Address correspondence to Dr. Schumock at the Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street (M/C 886), Chicago, IL 60612 (schumock{at}uic.edu).

Purpose. An overview of the emerging field of comparative effectiveness research (CER) and its relevance to pharmacists and pharmacy-based decision-makers is provided. Summary. The U.S. government is investing over $1 billion on CER over the next two years. This investment is in part driven by the recognition that, despite having the highest per capita health care expenditures in the world, the United States does not always perform well on measures of health compared with other countries. There also is increased awareness of the limited information provided by results of traditional randomized clinical trials to inform decisions about therapeutic alternatives as applied in actual practice. Comparative effectiveness studies have two important principal components: (1) the comparison of two or more agents or interventions that are considered true therapeutic alternatives and (2) the examination of effects (outcomes) in actual practice. Comparative effectiveness studies differ from traditional efficacy studies in several ways, including the research question addressed, comparison groups, patient population, setting, outcomes measured, and validity. Studies that are within the scope of CER can be categorized as primary comparative effectiveness studies or secondary comparative effectiveness studies. CER also can be used to compare medical devices, procedures, health services, or any competing intervention. Conclusion. Comparative effectiveness is an emerging area of research relevant to many areas of health care, especially pharmacotherapy. The knowledge gained from CER is important to pharmacists when applying drug information and making decisions related to drug therapy. Index terms: Clinical studies; Control, quality; Decision-making; Methodology; Outcomes; Pharmacists; Pharmacy; Quality assurance; Research